Observation on the efficacy of furmonertinib combined with GC chemotherapy in patients with non-small cell lung cancer
Objective To explore the clinical efficacy of the combination of furmonertinib and gemcitabine plus cisplatin(GC)chemotherapy regimen in patients with non-small cell lung cancer(NSCLC).Methods A total of 92 patients with NSCLC admitted to Xi'an Daxing Hospital from April 2021 to August 2022 were prospectively selected and were divided into two groups with 46 cases in each group by computer random number method.In the control group,there were 21 males and 25 females,aged(59.32±6.59)years,34 cases of stage Ⅲ and 12 cases of stage Ⅳ,26 cases of squamous cell carcinoma and 20 cases of adenocarcinoma.In the observation group,there were 24 males and 22 females,aged(58.41±6.37)years,31 cases of stage Ⅲ and 15 cases of stageⅣ,23 cases of squamous cell carcinoma and 23 cases of adenocarcinoma.The control group was given GC chemotherapy regimen:on day 1 to day 3,25 mg/m2 of cisplatin was mixed with 250 ml of normal saline for intravenous infusion,once a day;on day 1 and 8,1 000 mg/m2 of gemcitabine was mixed with 250 ml of normal saline for intravenous infusion,21 days as a chemotherapy cycle,for a total of 2 cycles.The observation group was given furmonertinib combined with GC chemotherapy regimen:GC chemotherapy regimen was the same as the control group,and oral furmonertinib was added since the first day of chemotherapy,40 mg each time,twice a day,for a total of 2 cycles.The efficacy,tumor markers,angiogenesis related factors,and drug safety were compared between the two groups.The patients were followed up for 1 year and the survival rates of the two groups were compared.x2 test,t test,and Log-rank test were used for statistical analysis.Results The objective remission rate(ORR)[52.18％(24/46)vs.28.26％(13/46)]and disease control rate(DCR)[93.48％(43/46)vs.78.26％(36/46)]in the observation group were higher than those in the control group(both P＜0.05).In the observation group,the levels of carcinoembryonic antigen(CEA)[(10.33±1.47)μg/L vs.(11.49±1.64)μg/L],neuron-specific enolase(NSE)[(13.52±1.93)μg/L vs.(14.76±2.11)μg/L],cytokeratin 19 fragment(CYFRA21-1)[(2.18±0.39)μg/L vs.(2.43±0.44)μg/L],carbohydrate antigen 125(CA125)[(36.25±4.53)U/ml vs.(39.47±4.93)U/ml],vascular endothelial growth factor(VEGF)[(365.48±45.69)ng/L vs.(395.47±49.43)ng/L],matrix metalloproteinase 9(MMP-9)[(101.21±11.25)mg/L vs.(107.68±11.96)mg/L],platelet-derived growth factor(PDGF)[(1 511.62±167.95)ng/L vs.(1 623.40±180.38)ng/L]were lower than those in the control group(all P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).The survival rate of the observation group was higher than that of the control group[89.13％(41/46)vs.69.56％(32/46)](P＜0.05).Conclusion The combination of furmonertinib and GC chemotherapy regimen for NSCLC patients can reduce the levels of tumor markers and angiogenesis related factors,inhibit tumor proliferation,improve efficacy,and has high drug safety and survival rate.
Non-small cell lung cancerFurmonertinibGemcitabine plus cisplatin chemotherapy regimenTumor markersSurvival analysis
万方数据
维普
